COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0
作者：
Miller, B. [1 ]
Russel-Szymczyk, M. [2 ]
Jensen, I. S. [3 ]
Shah, A. [1 ]
Alexopoulos, S. T. [4 ]
Herbert, A. [4 ]
McLean, T. [4 ]
Tundia, N. [5 ]
机构：
[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA
[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England
[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE658
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
[41]   Economic analysis for introduction of cladribine tablets as a treatment for relapsing-remitting and high disease activity multiple sclerosis in Kuwait [J].
Alroughani, R. ;
Al-Melh, M. A. ;
Farouk, S. ;
Abokoura, A. ;
Alsultan, E. ;
Boshra, A. ;
Alcharif, R. ;
Ojeil, R. ;
Basu, S. ;
Verma, A. .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) :310-311
[42]   Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK) [J].
Morgan, Kate ;
Lott, Nadine ;
Lyons, Marco .
NEUROLOGY, 2020, 94 (15)
[43]   Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis [J].
Hodgkinson, S. ;
Lizak, N. ;
Butler, E. ;
Lechner-Scott, J. ;
Slee, M. ;
McCombe, P. ;
Shaw, C. ;
Skibina, O. ;
Vucic, S. ;
Shuey, N. ;
Barnett, M. ;
Parratt, J. ;
Butzkueven, H. ;
Jack, D. ;
Fabris, J. ;
Kalincik, T. ;
Jokubaitis, V. G. .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) :NP64-NP65
[44]   Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis [J].
Brochet, Bruno ;
Hupperts, Raymond ;
Langdon, Dawn ;
Solari, Alessandra ;
Piehl, Fredrik ;
Lechner-Scott, Jeanette ;
Montalban, Xavier ;
Selmaj, Krzysztof ;
Valis, Martin ;
Havrdova, Eva ;
Rejdak, Konrad ;
Patti, Francesco ;
Alexandri, Nektaria ;
Nolting, Axel ;
Keller, Birgit .
NEUROLOGY, 2021, 96 (15)
[45]   COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST-LINE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM [J].
Alves, J. ;
Machado, M. .
VALUE IN HEALTH, 2015, 18 (07) :A878-A878
[46]   Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets: clarify-ms study interim analysis [J].
Brochet, B. ;
Hupperts, R. H. Raymond ;
Langdon, D. ;
Solari, A. ;
Piehl, F. ;
Lechner-Scott, J. ;
Montalban, X. ;
Selmaj, K. ;
Valis, M. ;
Rejdak, K. ;
Havrdova, E. Kubala ;
Patti, F. ;
Alexandri, N. ;
Nolting, A. ;
Keller, B. .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) :623-623
[47]   Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis [J].
Derfuss, T. ;
Bergvall, N. K. ;
Sfikas, N. ;
Tomic, D. L. .
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) :1687-1691
[48]   Earlier ofatumumab treatment May reduce disease progression and relapses for patients with relapsing-remitting multiple sclerosis: results from a cost-consequence model [J].
Green, L. ;
Montgomery, S. ;
Durand, A. ;
Loh, J. .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) :875-875
[49]   Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review [J].
Gavin Giovannoni ;
Joela Mathews .
Neurology and Therapy, 2022, 11 :571-595
[50]   Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know [J].
AlJumah, Mohamed ;
Alkhawajah, Mona Marwan ;
Qureshi, Shireen ;
Al-Thubaiti, Ibtisam ;
Ayoub, Omar ;
Bohlega, Saeed A. ;
Bushnag, Areej ;
Cupler, Edward ;
Daif, Abdulkader ;
El Boghdady, Ahmed ;
Hassan, Ahmed ;
Al Malik, Yaser ;
Saeedi, Jameelah ;
Al-Shamrany, Fawzia ;
Shosha, Eslam ;
Rieckmann, Peter .
NEUROLOGY AND THERAPY, 2020, 9 (01) :11-23
12345